Summary
A specific radioimmunoassay for the quantitative measurement of ACTH 4-10 and a procedure for its extraction from plasma have been developed.
Its pharmacokinetics was studied in eight healthy male volunteers given ACTH 4-10 125 µg/kg body weight as a bolus i.v. injection, by infusion and intranasally. Following the i.v. bolus, plasma levels rapidly declined biexponentially, with half-lives of 0.39±0.05 min for the α-phase and 3.84 ± 1.5 min for the β-phase (mean±SD). The constant rate i.v. infusion yielded steady-state levels between 0.74 and 5.06 ng/ml plasma. Administered as intranasal spray, absorption of intact ACTH 4-10 was low and variable (maximal bioavailability 7.6%).
The results are discussed in relation to the dose-dependent effects of ACTH 4-10 on the auditory evoked potential.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ambler L, Bennett HPJ, Hudson AU, McMartin C (1982) Fate of human corticotrophin immediately after intravenous administration to the rat. J Endocrinol 93: 287–292
Boarder UR, McArdle W (1986) Breakdown of small enkephalin derivatives and adrenal peptide E by human plasma. Biochem Pharmacol 35: 1043–1047
Born J, Fehm HL, Voigt KH (1986) ACTH and attention in humans: a review. Neuropsychobiology 15: 165–186
Born J, Bräuninger W, Fehm-Wolfsdorf G, Voigt KH, Pauschinger P, Fehm HL (1987a) Dose-dependent influences on electrophysiological signs of attention in humans after neuropeptide ACTH 4-10. Exp Brain Res 67: 85–92
Born J, Fehm-Wolfsdorf G, Voigt KH, Fehm HL (1987b) Influences of ACTH 4-10 on event related potentials in man. Physiol Behav 39: 83–89
de Wied D (1964) Influence of anterior pituitary on avoidance learning and escape behavior. Am J Physiol 207: 255–259
de Wied D (1966) Inhibitory effect of ACTH and related peptides on extinction of conditioned avoidance behavior in rats. Proc Soc Exp Biol Med 122: 28–32
de Wied D, Jolles J (1982) Neuropeptides derived from pro-opiocortin: behavioral, physiological and neurochemical effects. Physiol Revs 62: 976–1059
Greenwood FG, Hunter WU, Glover JS (1963) The preparation of125I-labelled human growth hormone of high specific activity. Biochem J 89: 114–123
Handelsman DJ, Swerdloff RS (1986) Pharmacokinetics of gonadotropin-releasing hormone and its analogs. Endocrinol Rev 7: 95–105
Hudson AU, McMartin C (1980) Mechanisms of catabolism of corticotrophin-(1-24)-tetracosapeptide in the rat in vivo. J Endocrinol 85: 93–103
Hussain A, Faraj J, Aramaki Y, Truelove JE (1985) Hydrolysis of leucine enkephalin in the nasal cavity of the rat — a possible factor in the low bioavailability of nasally administered peptides. Biochem Biophys Res Comm 133: 923–928
Koeppe P, Hamann C (1980) A program for non-linear regression analysis to be used on desk-top computers. Computer programs in Biomedicine 12: 121–128
Lambert A, Frost J, Ratcliffe WA, Robertson WR (1985) On the stability in vitro of bioactive human adrenocorticotrophin in blood and plasma. Clin Endocrinol 23: 253–261
Liechtensteiger W, Lienhart R (1977) Response of mesencephalic and hypothalamic DA neurons to α-MSH: Mediated by area postrema. Nature 266: 635–637
Loosen PT, Youngblood W, Dew B (1985) Plasma levels of exogenous thyrotropin-releasing hormone (TRH) in normal subjects: Relationship to endocrine and behavioral effects. Pharmacopsychiatry 18: 325–329
Luft FC, Lang RE, Aronoff GR, Ruskoaho H, Toth M, Ganten D, Sterzel RB, Unger T (1986) Atriopeptin III kinetics and pharmacodynamics in normal and anephric rats. J Pharmacol Exp Ther 236: 416–418
Nakanishi S, Inoue A, Kita T, Nakamura M, Chang AC, Cohen SN, Numa S (1979) Nucleotide sequence of cloned cDNA for bovine corticotropin-β-lipotropin precursor. Nature 278: 423–427
Van Houten M, Schiffrin EL, Mann JF, Posner BI, Boucher R (1980) Radioautographic localization of specific binding sites for blood-borne angiotensin II in the rat brain. Brain Res 186: 480–485
Van Houten M, Khan MN, Walsh RJ, Baquiran GB, Renaud LP, Bourque Ch, Sgro S, Gauthier S, Chretien M, Posner BI (1985) NH2-terminal specifity and axonal localization of adrenocorticotropin binding sites in rat median eminence. Proc Natl Acad Sci USA 82: 1271–1275
Van Nispen JW, Greven HM (1982) Structure-activity relationships of peptides derived from ACTH, β-LPH and MSH with regard to avoidance behavior in rats. Pharmacol Ther 16: 67–102
Verhoef J, Witter A (1976) In vivo fate of a behaviorally active ACTH 4-9 analog in rats after systemic administration. Pharmacol Biochem Behav 4: 583–590
Vilhardt H, Lundin S (1986) Biological effects and plasma concentrations of DDAVP after intranasal and peroral administration to humans. Gen Pharmacol 17: 481–483
Wagner JG (1975) Fundamentals of clinical pharmacokinetics. Drug Intelligence Publications, Hamilton, Illinois
Witter A, Greven HU, de Wied D (1975) Correlation between structure, behavioral activity and rate of biotransformation of some ACTH 4-9 analogs. J Pharmacol Exp Ther 193: 853–860
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bickel, U., Born, J., Fehm, H.L. et al. The behaviorally active peptide ACTH 4-10: Measurement in plasma and pharmacokinetics in man. Eur J Clin Pharmacol 35, 371–377 (1988). https://doi.org/10.1007/BF00561367
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00561367